Paper No. 19

Entered: August 16, 2017

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., Petitioner,

v.

ICOS CORPORATION, Patent Owner.

Case IPR2017-00323 Patent 6,943,166 B1

Before SHERIDAN K. SNEDDEN, SUSAN L. C. MITCHELL, and ZHENYU YANG, *Administrative Patent Judges*.

YANG, Administrative Patent Judge.

ORDER

Termination of the Proceeding Due to Settlement after Institution 35 U.S.C. § 317 and 37 C.F.R. § 42.72



With our authorization, the parties filed a Joint Motion to Terminate this proceeding pursuant to 35 U.S.C. § 317(a). Paper 16. In addition, pursuant to 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c), the parties filed a true and correct copy of a settlement agreement (Ex. 1038), along with a Joint Motion to Keep Settlement Agreement as Business Confidential Information, to be kept separate from the publicly available patent files. Paper 17.

Under 35 U.S.C. § 317(a), "[a]n inter partes review instituted under this chapter shall be terminated with respect to any petitioner upon the joint request of the petitioner and patent owner, unless the Office has decided the merits of the proceeding before the request for termination is filed." In this case, the Board instituted trial on June 12, 2017. Paper 12. So far, Patent Owner has not filed its Patent Owner Response, and the Board has not decided the merits of the proceeding.

Under 37 C.F.R. § 42.72, "[t]he Board may terminate a trial without rendering a final written decision, where appropriate, including . . . pursuant to a joint request under 35 U.S.C. 317(a)." After reviewing the Joint Motion to Terminate and the Settlement Agreement, we determine that it is appropriate to terminate the proceeding without rendering a final written decision. Therefore, the Joint Motion to Terminate is GRANTED.



IPR2017-00323 Patent 6,943,166 B1

Accordingly, it is

ORDERED that the Joint Motion to Terminate is GRANTED and this proceeding is hereby TERMINATED; and

FURTHER ORDERED that the Joint Motion to Keep Settlement Agreement as Business Confidential Information is GRANTED, and the settlement agreement will be kept separate from the patent files.

PETITIONER:

Steven W. Parmelee
Michael T. Rosato
Jad A. Mills
WILSON SONSINI GOODRICH & ROSATI
sparmelee@wsgr.com
mrosato@wsgr.com
jmills@wsgr.com

PATENT OWNER:

Mark J. Feldstein
Joshua L. Goldberg
Yieyie Yang
Maureen D. Queler
FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, LLP
mark.feldstein@finnegan.com
joshua.goldberg@finnegan.com
yieyie.yang@finnegan.com
maureen.queler@finnegan.com

Mark J. Stewart
Dan L. Wood
ELI LILLY AND COMPANY
stewart_mark@lilly.com
wood_dan_l@lilly.com

